Skip to main content
Figure 2 | Molecular Brain

Figure 2

From: Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimer’s disease

Figure 2

CSPalpha protein expression is reduced in Alzheimer’s disease hippocampus. (A) CSPalpha expression in post-mortem hippocampus from patients with severe Alzheimer’s disease (Braak stages 5 and 6; n = 12; average age at death = 75.2 ± 2.0 years) and control subjects (n = 12; average age at death = 76.5 ± 2.9 years). CSPalpha expression was normalized against the neuron-specific house keeping marker protein NSE. (B) CSPalpha expression in post-mortem hippocampus from patients with mild Alzheimer’s disease (Braak stages 1 and 2; n = 12; average age at death = 80.3 ± 3.2 years) and control subjects (n = 12). CSPalpha expression was normalized against NSE. (C) The same samples as in panel (A) were used but CSPalpha expression was normalized against the synaptic marker protein synaptophysin (severe Alzheimer’s disease, n = 11; control, n = 11). (D) The same samples as in panel (B) were used but CSPalpha expression was normalized against synaptophysin (mild Alzheimer’s disease, n = 12; control, n = 11). Panel (E) shows the representative western blots for 7 controls, 7 patients with severe AD and 7 patients with mild AD. Note that the anti-CSPalpha antibody recognizes two bands at an approximate molecular weight range of 35 kiloDalton, which are likely to represent distinct post-translational modifications of CSPalpha. Means ± s.e.m. are shown. *, p < 0.05; **, p < 0.01.

Back to article page